TEVA PHARMACEUTICAL INDUSTRIES LTD — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that TEVA PHARMACEUTICAL INDUSTRIES LTD filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.50B | Feb 3, 2026 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.26B | Feb 3, 2026 |
| FY2025 | Dec 31, 2024 | $16.54B | Feb 3, 2026 |
| FY2025 | Dec 31, 2023 | $15.85B | Feb 3, 2026 |
| FY2024 | Dec 31, 2022 | $14.93B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $15.88B | Feb 12, 2024 |
| FY2020 | Dec 31, 2020 | $4.45B | Feb 10, 2021 |
| FY2020 | Sep 30, 2020 | $3.98B | Feb 10, 2021 |
| FY2020 | Jun 30, 2020 | $3.87B | Feb 10, 2021 |
| FY2020 | Mar 31, 2020 | $4.36B | Feb 10, 2021 |
| FY2020 | Dec 31, 2019 | $4.47B | Feb 10, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.94B | Feb 3, 2026 |
| FY2025 | Dec 31, 2024 | $8.06B | Feb 3, 2026 |
| FY2025 | Dec 31, 2023 | $7.65B | Feb 3, 2026 |
| FY2024 | Dec 31, 2022 | $6.97B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $7.59B | Feb 12, 2024 |
| FY2020 | Dec 31, 2020 | $2.05B | Feb 10, 2021 |
| FY2020 | Sep 30, 2020 | $1.85B | Feb 10, 2021 |
| FY2020 | Jun 30, 2020 | $1.76B | Feb 10, 2021 |
| FY2020 | Mar 31, 2020 | $2.06B | Feb 10, 2021 |
| FY2020 | Dec 31, 2019 | $1.96B | Feb 10, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.41B | Feb 3, 2026 |
| FY2025 | Dec 31, 2024 | ($1.64B) | Feb 3, 2026 |
| FY2025 | Dec 31, 2023 | ($559.00M) | Feb 3, 2026 |
| FY2023 | Sep 30, 2023 | $70.00M | Feb 12, 2024 |
| FY2023 | Jun 30, 2023 | ($871.00M) | Feb 12, 2024 |
| FY2023 | Mar 31, 2023 | ($220.00M) | Feb 12, 2024 |
| FY2023 | Dec 31, 2022 | ($1.30B) | Feb 12, 2024 |
| FY2023 | Sep 30, 2022 | $61.00M | Feb 12, 2024 |
| FY2023 | Jun 30, 2022 | ($251.00M) | Feb 12, 2024 |
| FY2023 | Dec 31, 2021 | $417.00M | Feb 12, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.16B | Feb 3, 2026 |
| FY2025 | Dec 31, 2024 | ($303.00M) | Feb 3, 2026 |
| FY2025 | Dec 31, 2023 | $433.00M | Feb 3, 2026 |
| FY2023 | Sep 30, 2023 | $344.00M | Feb 12, 2024 |
| FY2023 | Jun 30, 2023 | ($654.00M) | Feb 12, 2024 |
| FY2023 | Mar 31, 2023 | ($13.00M) | Feb 12, 2024 |
| FY2023 | Dec 31, 2022 | ($940.00M) | Feb 12, 2024 |
| FY2023 | Sep 30, 2022 | $424.00M | Feb 12, 2024 |
| FY2023 | Jun 30, 2022 | ($967.00M) | Feb 12, 2024 |
| FY2023 | Dec 31, 2021 | $1.72B | Feb 12, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $98.00M | Feb 10, 2023 |
| FY2019 | Dec 31, 2018 | $114.00M | Feb 21, 2020 |
| FY2019 | Dec 31, 2017 | $175.00M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $422.00M | Feb 19, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.65B | Feb 3, 2026 |
| FY2025 | Dec 31, 2024 | $1.25B | Feb 3, 2026 |
| FY2025 | Dec 31, 2023 | $1.37B | Feb 3, 2026 |
| FY2024 | Dec 31, 2022 | $1.59B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $798.00M | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $1.22B | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $748.00M | Feb 9, 2022 |
| FY2020 | Dec 31, 2018 | $2.45B | Feb 10, 2021 |
| FY2019 | Dec 31, 2017 | $2.23B | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $3.89B | Feb 19, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $548.00M | Feb 10, 2023 |
| FY2022 | Dec 31, 2021 | $562.00M | Feb 10, 2023 |
| FY2022 | Dec 31, 2020 | $578.00M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $525.00M | Feb 9, 2022 |
| FY2020 | Dec 31, 2018 | $651.00M | Feb 10, 2021 |
| FY2019 | Dec 31, 2017 | $874.00M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $901.00M | Feb 19, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.75B | Feb 3, 2026 |
| FY2025 | Dec 31, 2024 | $39.33B | Feb 3, 2026 |
| FY2024 | Dec 31, 2023 | $43.48B | Feb 5, 2025 |
| FY2023 | Sep 30, 2023 | $42.10B | Feb 12, 2024 |
| FY2023 | Jun 30, 2023 | $43.10B | Feb 12, 2024 |
| FY2023 | Mar 31, 2023 | $43.46B | Feb 12, 2024 |
| FY2023 | Dec 31, 2022 | $44.01B | Feb 12, 2024 |
| FY2023 | Sep 30, 2022 | $44.25B | Feb 12, 2024 |
| FY2023 | Jun 30, 2022 | $45.93B | Feb 12, 2024 |
| FY2022 | Dec 31, 2021 | $47.67B | Feb 10, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.83B | Feb 3, 2026 |
| FY2025 | Dec 31, 2024 | $33.61B | Feb 3, 2026 |
| FY2024 | Dec 31, 2023 | $35.35B | Feb 5, 2025 |
| FY2023 | Sep 30, 2023 | $34.71B | Feb 12, 2024 |
| FY2023 | Jun 30, 2023 | $35.51B | Feb 12, 2024 |
| FY2023 | Mar 31, 2023 | $34.96B | Feb 12, 2024 |
| FY2023 | Dec 31, 2022 | $35.41B | Feb 12, 2024 |
| FY2023 | Sep 30, 2022 | $34.75B | Feb 12, 2024 |
| FY2023 | Jun 30, 2022 | $36.12B | Feb 12, 2024 |
| FY2022 | Dec 31, 2021 | $36.42B | Feb 10, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.91B | Feb 3, 2026 |
| FY2025 | Dec 31, 2024 | $5.37B | Feb 3, 2026 |
| FY2024 | Dec 31, 2023 | $7.51B | Feb 5, 2025 |
| FY2023 | Dec 31, 2022 | $7.80B | Feb 12, 2024 |
| FY2022 | Dec 31, 2021 | $10.28B | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $10.03B | Feb 9, 2022 |
| FY2020 | Dec 31, 2019 | $13.97B | Feb 10, 2021 |
| FY2019 | Dec 31, 2018 | $14.71B | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $17.36B | Feb 19, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.00B | Feb 3, 2026 |
| FY2025 | Dec 31, 2024 | $15.15B | Feb 3, 2026 |
| FY2025 | Dec 31, 2023 | $17.18B | Feb 3, 2026 |
| FY2025 | Dec 31, 2022 | $17.18B | Feb 3, 2026 |
| FY2024 | Dec 31, 2021 | $17.63B | Feb 5, 2025 |
| FY2022 | Dec 31, 2020 | $20.62B | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $24.85B | Feb 9, 2022 |
| FY2020 | Dec 31, 2018 | $24.92B | Feb 10, 2021 |
| FY2019 | Dec 31, 2017 | $28.41B | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $44.41B | Feb 19, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.76B) | Feb 3, 2026 |
| FY2025 | Dec 31, 2024 | ($15.17B) | Feb 3, 2026 |
| FY2024 | Dec 31, 2023 | ($13.53B) | Feb 5, 2025 |
| FY2023 | Sep 30, 2023 | ($14.00B) | Feb 12, 2024 |
| FY2023 | Jun 30, 2023 | ($14.07B) | Feb 12, 2024 |
| FY2023 | Mar 31, 2023 | ($13.19B) | Feb 12, 2024 |
| FY2023 | Dec 31, 2022 | ($12.98B) | Feb 12, 2024 |
| FY2023 | Sep 30, 2022 | ($11.67B) | Feb 12, 2024 |
| FY2023 | Jun 30, 2022 | ($11.73B) | Feb 12, 2024 |
| FY2022 | Dec 31, 2021 | ($10.53B) | Feb 10, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.56B | Feb 3, 2026 |
| FY2025 | Dec 31, 2024 | $3.30B | Feb 3, 2026 |
| FY2025 | Dec 31, 2023 | $3.23B | Feb 3, 2026 |
| FY2024 | Dec 31, 2022 | $2.80B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $2.17B | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $2.18B | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $1.98B | Feb 9, 2022 |
| FY2019 | Dec 31, 2018 | $1.78B | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $963.00M | Feb 19, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 3, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 3, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 3, 2026 |
| FY2023 | Sep 30, 2023 | 0 | Feb 12, 2024 |
| FY2023 | Jun 30, 2023 | 0 | Feb 12, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Feb 12, 2024 |
| FY2023 | Dec 31, 2022 | (1) | Feb 12, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Feb 12, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Feb 12, 2024 |
| FY2023 | Dec 31, 2021 | 0 | Feb 12, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 3, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 3, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 3, 2026 |
| FY2023 | Sep 30, 2023 | 0 | Feb 12, 2024 |
| FY2023 | Jun 30, 2023 | 0 | Feb 12, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Feb 12, 2024 |
| FY2023 | Dec 31, 2022 | (1) | Feb 12, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Feb 12, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Feb 12, 2024 |
| FY2023 | Dec 31, 2021 | 0 | Feb 12, 2024 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2018 | $12.00M | Feb 21, 2020 |
| FY2019 | Dec 31, 2017 | $901.00M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $1.30B | Feb 19, 2019 |